Prostate Cancer Diagnosis Articles & Analysis
24 news found
(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
Bot Image : Bot Image is a medical device company that created a product for post-processing MRI that is using artificial intelligence (AI) to aid physicians in image interpretation by providing highly accurate prostate cancer diagnostics. The software is provided as a SaaS model or can be installed behind the client’s firewall. CardioWise: CardioWise is ...
NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. Dr. Pankaj Jain at Arizona Urology said, “With our goal to offer the most advanced prostate cancer diagnostics and treatment ...
In clinical partnership with Promaxo, we look forward to optimizing clinical workflow for office-based MRI guided biopsies in our high volume practice, and to collaborating on prostate cancer treatments, including brachytherapy and post placement confirmatory scans of hydrogel with Promaxo's MRI ...
Profound subsequently signed the first site agreement for a TULSA-PRO® system interfaced with a GE scanner with Boston’s renowned Brigham and Women's Hospital. “Prostate cancer is the second most common cancer diagnosis and a leading cause of mortality in men worldwide1,” explained Anja Brau, General ...
As the recognized leader in PET prostate cancer diagnostic imaging, we are actively progressing our comprehensive prostate cancer portfolio, which includes 18F-fluciclovine and our investigational rhPSMA technology platform. ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and ...
BXCL701 plus KEYTRUDA (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to continue evaluation of BXCL701 combination as potentially differentiated approach for mCRPC patients Results support BXCL701’s potential to extend checkpoint inhibitor therapy into cold tumor settings BioXcel Therapeutics, Inc. ...
I find Curasight’s theranostic technology extremely promising; a technology that has the potential to disrupt the way cancer is diagnosed and treated. Curasight already has a great team and I’m glad to become part of it and the journey towards moving the technology as fast as possible towards clinical use for the benefit of cancer patients”, ...
About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.(1) At the time of ...
ByBayer AG
TORONTO, CANADA – Focal Healthcare, known globally as a leading innovator of image-guided prostate cancer technology, is diversifying their product line by developing an AI-based 3D ultrasound imaging platform. ...
Axumin, a novel amino acid-based radiopharmaceutical, is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically ...
Dr. James McKiernan, Professor of Urology at Columbia University, demonstrated that using the ExoDx Prostate test, or EPI, resulted in good performance ruling out high-grade (Gleason 7 or higher) prostate cancer (HGPCa) in prior negative biopsy patients with the previously validated 15.6 cut-point. Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, ...
The ExoDx™ Prostate (EPI) test played an important role in the management of Cal's prostate cancer. One in nine American men will be diagnosed with prostate cancer during their lifetime. Prostate cancer (PCa) is the second leading cause of cancer death ...
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial. The clinical trial, conducted at ...
Before we dive right into the performance of the prostate exam, let’s review a few prostate cancer statistics to highlight the importance of the exam. Prostate cancer is the second most common form of cancer in men (behind skin cancer) and the second leading cause of ...